Scheen André J
Université de Liège, service de diabétologie, nutrition et maladies métaboliques et unité de pharmacologie clinique, département de médecine, CHU de Liège, 4000 Liège, Belgique.
Rev Prat. 2011 Oct;61(8):1120-6.
Statins, combined with life-style advices, have a key position in the prevention of cardiovascular diseases. By inhibiting HMG-CoA reductase enzyme, these medications reduce total and LDL cholesterol levels in a dose-dependent manner. They also exert various pleiotropic effects that may contribute to the cardiovascular protection. Although some differences exist between available statins, a class effect seems predominant. Statins have proven their efficacy in numerous controlled randomized trials (recently pooled in meta-analyses), both in primary and secondary prevention, including various specific populations, among them patients with diabetes. Tolerance and safety profile is rather good even if muscular and hepatic adverse events may occur. The prescription of statins should target high-risk individuals and both therapeutic inertia and drug non-compliance should be avoided.
他汀类药物与生活方式建议相结合,在预防心血管疾病方面具有关键地位。通过抑制HMG-CoA还原酶,这些药物以剂量依赖的方式降低总胆固醇和低密度脂蛋白胆固醇水平。它们还发挥各种多效性作用,可能有助于心血管保护。尽管现有他汀类药物之间存在一些差异,但类效应似乎占主导。他汀类药物已在众多对照随机试验(最近汇总在荟萃分析中)中证明了其在一级和二级预防中的疗效,包括各种特定人群,其中有糖尿病患者。即使可能发生肌肉和肝脏不良事件,耐受性和安全性也相当好。他汀类药物的处方应针对高危个体,应避免治疗惰性和药物不依从性。